Please enable JavaScript.

Coggle requires JavaScript to display documents.

Case Study - Pfizer - Coggle Diagram

- - - - Phase 2: The Industry:
        Industrial guidelines & trends: Reduction in R&D funding, reduce in significant new drugs, expiring of "block-buster" drugs' patent.
        
        Phase 2: The Industry
        Trend: Shifting to Revolutionary Drugs from "Blockbuster" Drugs
  - - - Phase 3: The Firm
        Strategy: To maintain an industry-leading drug pipeline from in-house development to being more reliant on strategic partnerships and mergers and acquisitions with strong capabilities or revenue brands.
        
        Phase 3: The Firm
        Pricing Strategy: Increase price of expiring patent products
        
        Phase 3: The Firm
        Products Category:
        Established - focus on branded generic medicines and legacy brands that have lost or will lose market exclusivity in the short-term to development and commercialization or
        Innovative - development and commercialization of new medicines and vaccines
        
        Phase 3: The Firm
        Main Market: US & Japan
        Marketing to healthcare provider & patients by providing education talk on products usage, benefits, risks, etc.
        
        Phase 3: The Firm
        Financial: revenues have been steadily decreasing, reducing net income to a five-year low of $6.96 billion. balance sheet
        has been fairly steady the past two years